Skip to content
Screener

BioMarin Pharmaceuticals BMRN Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$00.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$0.010.0%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX

Other financials

Income statement

See full
Revenue$989.7M+19.9%
Gross profit$786.9M+16.5%
Operating income$110.9M-59.9%
Net income$44.8M-81.4%
EPS (diluted)$0.23-81.3%

Balance sheet

See full
Cash & equivalents$874.0M-28.0%
Total debt$4.2B+598%
Total equity$6.3B+4.9%
Total assets$11.7B+57.2%

Cash flow

See full
Operating cash flow$168.1M-9.3%
CapEx$28.8M+68.5%
Free cash flow$139.3M-17.2%

Valuation

See full
Market cap$12.35B+12.2%
Enterprise value$15.66B+50.7%
P/E34.3×-37.0×
P/S3.6×0.0×

Profitability

See full
Gross margin76.1%-3.4pp
Operating margin19.9%+7.2pp
Net margin16.8%+5.1pp
FCF margin21.7%-1.0pp

Returns & leverage

See full
Return on equity9.1%+2.8pp
Debt / equity0.7×+0.6×
Current ratio2.4×-3.2×

Where this comes from

Reported directly by BioMarin Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001048477-26-000016
ASSETSJune 30, 2026 / (unaudited)December 31, 2025 ⁽¹⁾
Other long-term liabilities209,815150,816
Total liabilities5,401,7501,507,023
Stockholders’ equity:
Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively194192
Additional paid-in capital6,037,0195,956,582
Company common stock held by the Nonqualified Deferred Compensation Plan(11,233)(10,508)
Accumulated other comprehensive loss(8,783)(13,473)
Retained earnings304,495154,206

Item 1. Financial Statements

FAQ

What is BioMarin Pharmaceuticals's common stock, par value (in dollars per share)?
BioMarin Pharmaceuticals (BMRN) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has BioMarin Pharmaceuticals's common stock, par value (in dollars per share) changed year-over-year?
BioMarin Pharmaceuticals's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for BioMarin Pharmaceuticals's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about BioMarin Pharmaceuticals's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude